Data from the phase 3 MANGROVE study support the application for zanubrutinib/rituximab in this mantle cell lymphoma population.
News|Videos|December 15, 2017
HCT Consolidation Improves Survival in Younger MCL Patients
Author(s)Brian T. Hill, MD, PhD
This video highlights results of a retrospective review that examined survival and other outcomes in younger mantle cell lymphoma (MCL) patients who received consolidation with autologous hematopoietic cell transplant during first remission.
Advertisement
In this video, Brian T. Hill, MD, PhD, of the Cleveland Clinic in Ohio, discusses results of a retrospective review that examined survival and other outcomes in younger mantle cell lymphoma (MCL) patients who received consolidation with autologous hematopoietic cell transplant (HCT) during first remission.
Results of the study (
Advertisement
Related to this article
In the phase 2 DALY 2-EU trial, zamto-cel prolonged median event-free survival vs R-GemOx in transplant-ineligible relapsed/refractory large B-cell lymphoma.
Rocbrutinib plus R-CHOP yielded a 100% ORR and an 86.7% CR rate in 15 patients with untreated non-GCB DLBCL, warranting randomized evaluation.
Grade 3/4 neurotoxicity in patients prompted a partial clinical hold on the PALISADES-1 and PALISADES-2 trials of KITE-753 in large B-cell lymphoma.
In a phase 2 trial, orelabrutinib plus sintilimab yielded a 60.7% overall response rate in relapsed/refractory primary CNS lymphoma.
Advertisement
Advertisement
Trending on CancerNetwork
1
MASLD Raises Liver and Other Cancer Risks, Supporting Selective HCC Surveillance
2
BOT+BAL Yields Long-Term Survival in Patients With Refractory MSS mCRC
3
Tambiciclib Combo Shows Activity in Relapsed/Refractory Post-Venetoclax AML
4
Weighing Immunotherapy for Bridging and Downstaging Before HCC Transplant
5